SCHEMBL10243178

SCHEMBL10243178

CCNC(=O)OCc1cccc(-c2ccco2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 1/20 0.52
PSMB5 P28074 3/20 0.45
KEAP1 Q14145 1/20 0.45
TSHR P16473 3/20 0.43
CTSL P07711 2/20 0.43
CTSB P07858 2/20 0.43
CTSS P25774 2/20 0.43
CTSK P43235 2/20 0.43
ALDH1A1 P00352 6/20 0.43
KDM4E B2RXH2 3/20 0.43
HDAC1 Q13547 2/20 0.42
HDAC6 Q9UBN7 2/20 0.42
HPGD P15428 3/20 0.41
MGLL Q99685 1/20 0.40
MAPT P10636 3/20 0.40
POLB P06746 2/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243163 0.82 PRMT6 (0.59) PRMT6PSMB5KEAP1TSHRALDH1A1
SCHEMBL10242931 0.81 PRMT6 (0.56) PRMT6PSMB5KEAP1CTSSCTSK
SCHEMBL10242910 0.79 PRMT6 (0.53) PRMT6PSMB5KEAP1TSHRCTSL
SCHEMBL14233717 0.76 LMNA (0.45) MGLLMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL5662919 0.75 PRMT6 (0.58) PRMT6PSMB5KEAP1ALDH1A1KDM4E
SCHEMBL10242941 0.75 KEAP1 (0.61) PRMT6KEAP1TSHRALDH1A1KDM4E
SCHEMBL10243039 0.74 LMNA (0.44) MGLLMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL10242970 0.74 GLA (0.54) KDM4EMEN1KMT2A
SCHEMBL25852781 0.74 HCAR2 (0.54) TSHRALDH1A1KDM4EHPGDMEN1
SCHEMBL1016234 0.74 PRMT6 (0.58) PRMT6PSMB5KEAP1CTSBCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 PRMT6 1751/4885PSMB5 3215/4885KEAP1 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.